Information Provided By:
Fly News Breaks for April 6, 2017
SGYP
Apr 6, 2017 | 05:44 EDT
Citi analyst Liav Abraham downgraded Synergy Pharmaceuticals to Sell saying she sees downside over the next two years to both sales and operating income consensus estimates. The analyst believes the Trulance launch is likely to disappoint and that a takeover appears unlikely. Abraham cut her price target for Synergy shares to $3.70 from $6.50 after removing any takeover premium.
News For SGYP From the Last 2 Days
There are no results for your query SGYP